Clinical Trials Sponsored by First Affiliated Hospital of Zhengzhou University, China

Total 2995 results

First Affiliated Hospital of Zhejiang University
The First Affiliated Hospital of Zhengzhou University; First Affiliated Hospital... and other collaborators

Unknown

A Prospective, Multicenter Clinical Trial of Safety and Effectiveness of Nanosecond Knife Ablation for Liver Cancer

Liver Cancer
The First Affiliated Hospital of Zhengzhou University

Recruiting

Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer

Metastatic Colorectal Cancer

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Effect of Botulinum Toxin Injection Into Upper Esophageal Sphincter in Patients With Medullary Infarction

Brain Stem Infarctions | Dysphagia, Esophageal | Dysphagia, Oropharyngeal

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Mindfulness Yoga and Sexual Functioning

Breast Cancer | Sexual Dysfunction

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer

Advanced Colorectal Cancer
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage Ⅱ and Stage Ⅲ Colon Cancer and dMMR/MSI.

Colon Cancer
The First Affiliated Hospital of Zhengzhou University

Recruiting

An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer

Breast Cancer | Breast Cancer Female

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

AK105 Combined With Anlotinib in Patients With Cervical Cancer

Cervical Cancer
The First Affiliated Hospital of Zhengzhou University

Recruiting

Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Metastatic Gastric Cancer

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas

Recurrent Glioma

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Primary Ovarian Insufficient Patients

Healthy Related

China
The First Affiliated Hospital of Zhengzhou University

Active, not recruiting

Tislelizumab in Addition to BACE in Patients With NSCLC

NSCLC

China
The First Affiliated Hospital of Zhengzhou University

Completed

Site Selection of Short Peripheral Venous Catheters (SPECIAL)

Short Peripheral Venous Catheter

China
The First Affiliated Hospital of Zhengzhou University

Unknown

Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Advanced Esophageal Squamous Carcinoma

China
The First Affiliated Hospital of Zhengzhou University

Unknown

The Application of Time-lapse System in IVF/ICSI

the Application of Time-lapes System in IVF/ICSI

China
The First Affiliated Hospital of Zhengzhou University

Unknown

The Effectiveness of Endometrial Injury in IVF

Infertility

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Effect of Botulinum Toxin Injection Guided by Ultrasound Combined With Balloon Localization on Cricopharyngeal Achalasia

Dysphagia | Cricopharyngeal Achalasia

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Cortical Function Changes During Swallowing in Patients With Dysphagia in Lateral Medullary Syndrome

Deglutition Disorders | Lateral Medullary Syndrome

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)

Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC

Esophageal Cancer by AJCC V8 Stage

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Esophageal Arterial Infusion Chemotherapy Versus Systemic Intravenous Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Prospective, Multicentre, Randomised Controlled Clinical Study

Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University

Recruiting

Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer (AIPAAIAEC)

Esophageal Neoplasms

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome (GBS-PRAISING)

Guillain-Barre Syndrome

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell Carcinoma

Locally Advanced Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC

Stomach Cancer

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer

Esophageal Cancer

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC

Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Survival Significance of Molecular Pathology and Genetic Variation in Brain Gliomas

Glioma | Molecular Sequence Variation | Genetic Change

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Azoospermia Patients

Healthy Related

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

PCOS (Polycystic Ovarian Syndrome) Patients

Health Related

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Study of Anti-PD-1/PD-L1 Antibody Plus Apatinib as Second-Line Treatment of Advanced Esophageal Squamous Cell

Esophageal Cancer

China
The First Affiliated Hospital of Zhengzhou University

Completed

Genetic Research on High Myopic Individuals in Northern China

High Myopia

China
The First Affiliated Hospital of Zhengzhou University

Unknown

Botulinum Toxin for Trigeminal Neuralgia (EASTERN)

Trigeminal Neuralgia

China
The First Affiliated Hospital of Zhengzhou University

Unknown

Effect of Shorten Gonadotropin-releasing Hormone Agonist Therapy on the Outcome of in Vitro Fertilization-Embryo Transfer in Patients With Endometriosis

Clinical Pregnancy Rate

China
The First Affiliated Hospital of Zhengzhou University

Completed

Aminophylline for Patients With Post-Dural Puncture Headache

Post-dural Puncture Headache

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 Stage

Gastric Cancer

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)

Esophageal Squamous Cell Carcinoma (ESCC) | PD-1 Inhibitors

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer

Capecitabine | MSI-H Colorectal Cancer | Oxaliplatin | Tislelizumab
The First Affiliated Hospital of Zhengzhou University

Recruiting

Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer

Advanced Biliary Tract Cancer

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion

Malignant Pleural Effusion
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Cancer

Gastric Cancer

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC

Esophageal Cancer

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma

Resectable Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University

Recruiting

Newborns From Patients Treated With ART (Assisted Reproductive Technology)

Health Related

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
The First Affiliated Hospital of Zhengzhou University

Active, not recruiting

Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)

Esophageal Squamous Cell Carcinoma

China

Clinical Trials Sponsored by First Affiliated Hospital of Zhengzhou University, China

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations